Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis.
Listing, J
Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. [electronic resource] - Annals of the rheumatic diseases Dec 2004 - 1670-2 p. digital
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial
0003-4967
10.1136/ard.2003.017327 doi
Adult
Antibodies, Monoclonal--therapeutic use
Antirheumatic Agents--therapeutic use
Cost of Illness
Double-Blind Method
Female
Follow-Up Studies
Germany
Hospitalization--statistics & numerical data
Humans
Infliximab
Male
Middle Aged
Sick Leave--statistics & numerical data
Spondylitis, Ankylosing--drug therapy
Tumor Necrosis Factor-alpha--antagonists & inhibitors
Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. [electronic resource] - Annals of the rheumatic diseases Dec 2004 - 1670-2 p. digital
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial
0003-4967
10.1136/ard.2003.017327 doi
Adult
Antibodies, Monoclonal--therapeutic use
Antirheumatic Agents--therapeutic use
Cost of Illness
Double-Blind Method
Female
Follow-Up Studies
Germany
Hospitalization--statistics & numerical data
Humans
Infliximab
Male
Middle Aged
Sick Leave--statistics & numerical data
Spondylitis, Ankylosing--drug therapy
Tumor Necrosis Factor-alpha--antagonists & inhibitors